Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04501081 · ClinicalTrials.gov registry record
Natural History of Autosomal Dominant Hearing Loss
A clinical trial of Hearing Loss, sponsored by National Institute on Deafness and Other Communication Disorders (NIDCD).
- Recruiting
- Registry status
- 1,100
- Enrollment target
- 1
- Study location
NCT04501081: Recruiting study of Hearing Loss, sponsored by National Institute on Deafness and Other Communication Disorders (NIDCD).
NCT04501081 is a study of Hearing Loss that is actively recruiting participants, run by National Institute on Deafness and Other Communication Disorders (NIDCD). The registered enrollment target is 1,100 participants, below the 6,102-participant average among 58 other Hearing Loss trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04501081, a study of Hearing Loss, is actively recruiting participants, sponsored by National Institute on Deafness and Other Communication Disorders (NIDCD).
- RECRUITING
- Registry status
- 1,100 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Hereditary hearing loss is one of the most common sensory disabilities affecting newborns. The main options for people with hereditary hearing loss are hearing aids and cochlear implants. Both options have their limitations and do not restore biological hearing. Researchers want to learn if gene editing might be a treatment option. Objective: To understand the genes that cause non-syndromic autosomal dominant hearing loss (DFNA) in people with DFNA as well as their family members. Eligibility: People age 3 99 who have DFNA, affected family members of enrolled participants with DFNA, and unaffected family members of enrolled participants Design: Participants will be screened with a medical and hearing history. Their medical records will be reviewed. Participants will have hearing tests. They will wear headphones or earplugs. They will listen to tones, sounds, and words and may be asked to describe what they hear. Participants will have balance tests. For these, they will wear googles as they watch moving lights or as cold or warm air is blown into their ears. They will sit in a spinning chair in a quiet, dark booth. From a reclined position, they will raise their head while listening to clicking sounds. Participants will have blood drawn through a needle in the arm. Some blood will be used for gene testing. Some participants will have 2 skin biopsies. The skin will be washed, and a numbing medicine will be injected. Two small pieces of skin will be removed. Participants may have a physical exam. Participation will last for up to 20 years. Participants may give medical updates once a year.
Primary Outcome
After determination of the genetic mutation involved with the hearing loss, gRNAs will be generated which will target the mutation in individual probands. Specific outcome measures that will be collected include, 1) testing the efficiency of individual gRNAs at inducing genome editing in primary or immortalized fibroblast cultures from DFNA patients, and 2) assessing the specificity of individual gRNAs at inducing genome editing in both the mutant10. The efficiency of individual gRNAs at inducin
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,100 participants |
| Start Date | 2021-02-09 |
| Est. Completion | 2029-08-21 |
What NCT04501081 shows while recruiting
NCT04501081 is an observational study that tracks outcomes without assigning an intervention. Its 1,100 participants enrollment target places it among the larger protocols in the corpus, below the 6,102-participant average among 58 other Hearing Loss trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Hearing Loss appearing as the primary indexed condition, and to 0 interventions.
NCT04501081 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT04501081 about?
NCT04501081 is a clinical study titled "Natural History of Autosomal Dominant Hearing Loss". Background: Hereditary hearing loss is one of the most common sensory disabilities affecting newborns. The main options for people with hereditary hearing loss are hearing aids and cochlear implants. Both options have their limitations and do not restore biological hearing. Researchers want to lear...
What is the current status of trial NCT04501081?
This trial is currently recruiting. The enrollment target is 1,100 participants. The study started on 2021-02-09. Estimated completion is 2029-08-21.
What conditions does trial NCT04501081 study?
This clinical trial studies the following conditions: Hearing Loss.
Who is sponsoring clinical trial NCT04501081?
This trial is sponsored by National Institute on Deafness and Other Communication Disorders (NIDCD), which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04501081 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hearing Loss
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04501081's enrollment target sits among peer trials
1,100 7th of 58 higher than 52 of 58 other Hearing Loss trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hearing Loss trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Access and Affordability of Adult Hearing Healthcare
RECRUITING · NA
-
AI Noise Reduction in Phonak Hearing Aids
RECRUITING · NA
-
Investigation of a Device to Deliver Intra-Operative Therapeutic Hypothermia for Hearing Preservation in Cochlear Implantation
RECRUITING · NA
-
Auditory-Cognitive Training to Optimize Outcomes for Older CI Users
RECRUITING · NA
-
Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors
RECRUITING · Phase 1
-
NIDCD Otolaryngology Clinical Protocol Biospecimen Bank
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00710112 · 1,100 participants
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
- NCT02688517 · 1,100 participants
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
- NCT04743765 · 1,100 participants · NA
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
- NCT05638581 · 1,100 participants · Phase 3
Trauma Resuscitation With Low-Titer Group O Whole Blood or Products
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI